Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)

Απλή σελίδα τεκμηρίου
dc.contributor.authorMilionis, H. J.en
dc.contributor.authorRizos, E.en
dc.contributor.authorKostapanos, M.en
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorGazi, I. F.en
dc.contributor.authorGanotakis, E. S.en
dc.contributor.authorGoudevenos, J.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T19:08:45Z
dc.date.available2015-11-24T19:08:45Z
dc.identifier.issn0300-7995-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20587
dc.rightsDefault Licence-
dc.subjectBlood Proteins/analysisen
dc.subjectFemaleen
dc.subjectFluorobenzenes/*administration & dosageen
dc.subjectHeptanoic Acids/*administration & dosageen
dc.subjectHumansen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosageen
dc.subjectHyperlipidemias/blood/*drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPyrimidines/*administration & dosageen
dc.subjectPyrroles/*administration & dosageen
dc.subjectSulfonamides/*administration & dosageen
dc.subjectTriglycerides/blooden
dc.titleTreating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)en
heal.abstractOBJECTIVES: In a 24-week, open-label, randomized, parallel-group study, we compared the efficacy and metabolic effects, beyond low density lipoprotein cholesterol (LDL-C)-lowering, of atorvastatin (ATV) and rosuvastatin (RSV) in cardiovascular disease-free subjects with primary hyperlipidaemia, treated to an LDL-C target (130 mg/dL). METHODS: After a 6-week dietary lead-in period, patients were randomized to RSV 10 mg/day (n = 60) or ATV 20 mg/day (n = 60). After 6 weeks on treatment the dose of the statin was increased (to RSV 20 mg/day or ATV 40 mg/day) if the treatment goal was not achieved. A control group of healthy volunteers (n = 60) was also included for the validation of baseline serum and urinary laboratory parameters. The primary outcome was the percentage of patients reaching the LDL-C goal; secondary outcomes were changes in lipid and non-lipid metabolic parameters. RESULTS: A total of 45 patients (75.0%) in the RSV-treated group and 43 (71.7%) in the ATV-treated group achieved the treatment target at the initial dose. Both regimens were generally well tolerated and there were no withdrawals due to treatment-related serious adverse events. Similar significant reductions in total cholesterol, LDL-C, apolipoprotein (apo) B, triglycerides, apoB/apoA1 ratio, fibrinogen and high-sensitivity C-reactive protein levels were seen. RSV had a significant high density lipoprotein cholesterol (HDL-C)-raising effect and showed a trend towards increasing apoA1 levels. Glycaemic control and renal function parameters were not influenced by statin therapy. ATV, but not RSV, showed a significant hypouricaemic effect. CONCLUSIONS: RSV and ATV were equally efficacious in achieving LDL-C treatment goals in patients with primary hyperlipidaemia at the initial dose and following dose titration. RSV seems to have a significantly higher HDL-C-raising effect, while ATV lowers serum uric acid levels.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1185/030079906X112462-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16846545-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.1185/030079906X112462-
heal.journalNameCurrent Medical Research and Opinionen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2006-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ